Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
In recent years, several associations between common chronic human disorders and altered gut microbiome composition and function have been reported. In most of these reports, treatment regimens were not controlled for and conclusions could thus be confounded by the effects of various drugs on the microbiota, which may obscure microbial causes, protective factors or diagnostically relevant signals. Our study addresses disease and drug signatures in the human gut microbiome of type 2 diabetes mellitus (T2D). Two previous quantitative gut metagenomics studies of T2D patients that were unstratified for treatment yielded divergent conclusions regarding its associated gut microbial dysbiosis. Here we show, using 784 available human gut metagenomes, how antidiabetic medication confounds these results, and analyse in detail the effects of the most widely used antidiabetic drug metformin. We provide support for microbial mediation of the therapeutic effects of metformin through short-chain fatty acid production, as well as for potential microbiota-mediated mechanisms behind known intestinal adverse effects in the form of a relative increase in abundance of Escherichia species. Controlling for metformin treatment, we report a unified signature of gut microbiome shifts in T2D with a depletion of butyrate-producing taxa. These in turn cause functional microbiome shifts, in part alleviated by metformin-induced changes. Overall, the present study emphasizes the need to disentangle gut microbiota signatures of specific human diseases from those of medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patient treatment with the drug metformin, a variable that subjects had not been stratified for previously, constituted the main determinant of microbial signatures in diabetic cohorts [62].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [62]
In the citing paper
“This action is an important determinant for the anti-hyperglycemic therapeutic effects, the gastrointestinal side effects and possibly the anti-aging effects of metformin (88, 89).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [88]
In the citing paper
“As for C. elegans, metformin use in humans will change the microbiome.”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [88]
In the citing paper
“Studies comparing individuals with T2D treated or not with metformin identified a higher level of E. coli and a lower level of Intestinibacter in the metformin-treated individuals, while confirming reduced levels of butyrate-producing bacteria such as Roseburia spp., F. prausnitzii, and unnamed Clostridiales in the untreated individuals compared to healthy controls5, 6, 34, 35.”
From The gut microbiome in atherosclerotic cardiovascular disease (2017) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
FLASH: fast length adjustment of short reads to improve genome assemblies
Magoč, T., & Salzberg, S. L. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr507 · Cited by 15,366
UCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
A new method for non-parametric multivariate analysis of variance
Anderson, M. J. (2001) · Austral Ecology · doi:10.1111/j.1442-9993.2001.01070.pp.x · Cited by 13,828
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
VEGAN, a package of R functions for community ecology
Dixon, P. (2003) · Journal of Vegetation Science · doi:10.1111/j.1654-1103.2003.tb02228.x · Cited by 6,824
Cited by
Items 401–500 of 1,006
Barengolts, E., Green, S. J., Eisenberg, Y., Akbar, A., Reddivari, B., Layden, B. T., Dugas, L., & Chlipala, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194171 · Cited by 111
Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models
Allesøe, R. L., Lundgaard, A. T., Hernández Medina, R., Aguayo-Orozco, A., Johansen, J., Nissen, J. N., Brorsson, C., Mazzoni, G., Niu, L., Biel, J. H., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01520-x · Cited by 111
Self-citationFunctional Genomics of Host–Microbiome Interactions in Humans
Luca, F., Kupfer, S. S., Knights, D., Khoruts, A., & Blekhman, R. (2018) · Trends in Genetics · doi:10.1016/j.tig.2017.10.001 · Cited by 100
Frugé, A. D., Pol, W. V. D., Rogers, L. Q., Morrow, C. D., Tsuruta, Y., & Demark‐Wahnefried, W. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.08.164 · Cited by 111
Woody Plant Declines. What’s Wrong with the Microbiome?
Bettenfeld, P., Fontaine, F., Trouvelot, S., Fernández, O., & Courty, P. (2020) · Trends in Plant Science · doi:10.1016/j.tplants.2019.12.024 · Cited by 111
Akkermansia muciniphila plays critical roles in host health
Zhao, Q., Yu, J., Hao, Y., Zhou, H., Hu, Y., Zhang, C., Zheng, H., Wang, X., Zeng, F., Hu, J., et al. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2037506 · Cited by 111
Self-citationKynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?
Kozieł, K., & Urbańska, E. M. (2023) · Cells · doi:10.3390/cells12030460 · Cited by 113
Yan, X., Feng, B., Li, P., Tang, Z., & Wang, L. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2093171 · Cited by 110
Pröbstel, A.-K., & Baranzini, S. E. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0587-y · Cited by 110
Effects of garlic polysaccharide on alcoholic liver fibrosis and intestinal microflora in mice
Wang, Y., Guan, M., Zhao, X., & Li, X. (2018) · Pharmaceutical Biology · doi:10.1080/13880209.2018.1479868 · Cited by 110
“In recent years, several associations between common chronic human disorders and altered intestinal microflora composition and function have been reported (Forslund et al. 2015).”
Madempudi, R. S., Ahire, J. J., Neelamraju, J., Tripathi, A., & Nanal, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225168 · Cited by 110
Interactions of commensal and pathogenic microorganisms with the mucus layer in the colon
Cai, R., Chen, C., Chen, J., Xu, X., Ding, C., & Gu, B. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1735606 · Cited by 111
Understanding immune–microbiota interactions in the intestine
Ahern, P. P., & Maloy, K. J. (2020) · Immunology · doi:10.1111/imm.13150 · Cited by 99
Su, J., Li, D., Chen, Q., Li, M., Su, L., Luo, T. L., Liang, D., Lai, G., Shuai, O., Jiao, C., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03099 · Cited by 108
Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India
Silva, M. C. A., Kashani, A., Hansen, T. H., Pinna, N. K., Anjana, R. M., Dutta, A., Saxena, S., Støy, J., Kampmann, U., Nielsen, T., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00856-4 · Cited by 108
Self-citationMetformin Protects against LPS-Induced Intestinal Barrier Dysfunction by Activating AMPK Pathway
Wu, W.-C., Wang, S., Liu, Q., Shan, T., & Wang, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00332 · Cited by 107
Baxter, N. T., Lesniak, N. A., Sinani, H., Schloss, P. D., & Koropatkin, N. M. (2019) · mSphere · doi:10.1128/msphere.00528-18 · Cited by 107
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Verdura, S., Cuyàs, E., Martin-Castillo, B., & Menendez, J. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1633235 · Cited by 98
Peng, W., Huang, J., Yang, J., Zhang, Z., Yu, R., Fayyaz, S., Zhang, S., & Qin, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03141 · Cited by 107
The Metabolic Role and Therapeutic Potential of the Microbiome
Olofsson, L. E., & Bäckhed, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac004 · Cited by 92
Nutritional Aspects of Iron in Health and Disease
Charlebois, E., & Pantopoulos, K. (2023) · Nutrients · doi:10.3390/nu15112441 · Cited by 108
Pathogenic functions of host microbiota
Rath, S., Rud, T., Karch, A., Pieper, D. H., & Vital, M. (2018) · Microbiome · doi:10.1186/s40168-018-0542-0 · Cited by 106
Microbiota and Diabetes Mellitus: Role of Lipid Mediators
Salazar, J. J., Angarita, L., Morillo, V., Navarro, C., Martínez, M. S., Chacín, M., Torres, W., Rajotia, A., Rojas, M., Cano, C., et al. (2020) · Nutrients · doi:10.3390/nu12103039 · Cited by 106
Herreweghen, F. V., den Abbeele, P. V., Mulder, T. D., Weirdt, R. D., Geirnaert, A., Hernandez‐Sanabria, E., Vilchez‐Vargas, R., Jáuregui, R., Pieper, D. H., Belzer, C., et al. (2016) · Beneficial Microbes · doi:10.3920/bm2016.0013 · Cited by 106
Tagliamonte, S., Laiola, M., Ferracane, R., Vitale, M., Gallo, M. A., Meslier, V., Pons, N., Ercolini, D., & Vitaglione, P. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02538-8 · Cited by 105
Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity
McEvoy, L., Carr, D. F., & Pirmohamed, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684162 · Cited by 106
The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus
Crăciun, C.-I., Neag, M. A., Cătinean, A., Mitre, A. O., Rusu, A., Bala, C. G., Román, G., Buzoianu, A. D., Muntean, D. M., & Craciun, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020308 · Cited by 105
Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps
Liang, S., Mao, Y. K., Liao, M., Xu, Y., Chen, Y.-C., Huang, X., Wei, C., Wu, C., Wang, Q., Pan, X., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.37399 · Cited by 104
Enterotype Bacteroides Is Associated with a High Risk in Patients with Diabetes: A Pilot Study
Wang, J., Li, W., Wang, C., Wang, L., He, T., Hu, H., Song, J., Cui, C., Qiao, J., Qing, L., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6047145 · Cited by 103
Self-citationAssessment of fecal DNA extraction protocols for metagenomic studies
Yang, F., Sun, J., Luo, H., Ren, H., Zhou, H., Lin, Y., Han, M., Chen, B., Liao, H., Brix, S., et al. (2020) · GigaScience · doi:10.1093/gigascience/giaa071 · Cited by 103
Self-citationGut microbiome and lipid metabolism: from associations to mechanisms
Wang, Z., Koonen, D., Hofker, M., & Fu, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000308 · Cited by 93
Personalized medicine in diabetes: the role of ‘omics’ and biomarkers
Pearson, E. R. (2016) · Diabetic Medicine · doi:10.1111/dme.13075 · Cited by 94
Moon, J., Zolnik, C. P., Wang, Z., Qiu, Y., Usyk, M., Wang, T., Kizer, J. R., LANDAY, A. L., Kurland, I. J., Anastos, K., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.037 · Cited by 104
Davies, N., O'Sullivan, J. M., Plank, L. D., & Murphy, R. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.01.033 · Cited by 102
Szymczak-Pajor, I., Wenclewska, S., & Śliwińska, A. (2022) · Pharmaceuticals · doi:10.3390/ph15070810 · Cited by 101
Immunologic impact of the intestine in metabolic disease
Winer, D. A., Winer, S., Dranse, H. J., & Lam, T. K. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88879 · Cited by 86
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33557 · Cited by 100
Marcial-Coba, M. S., Cieplak, T., Cahú, T. B., Blennow, A., Knøchel, S., & Nielsen, D. S. (2018) · Food & Function · doi:10.1039/c8fo01331d · Cited by 101
Role of the microbiome in occurrence, development and treatment of pancreatic cancer
Wang, Y., Yang, G., You, L., Yang, J., Feng, M., Qiu, J., Zhao, F., Liu, Y., Cao, Z., Zheng, L., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1103-2 · Cited by 102
Wang, X., Yang, Z., Xu, X., Jiang, H., Cai, C., & Yu, G. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116261 · Cited by 100
The effects of metformin on gut microbiota and the immune system as research frontiers
Pollak, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4352-x · Cited by 98
“There is convincing evidence [19, 20] that metformin exposure induces significant changes in human intestinal microbiota (for example, decreases in abundance of Intestinibacter), and in the gut metabolome (for example, increased butyrate production).”
Metaproteomics as a Complementary Approach to Gut Microbiota in Health and Disease
Petriz, B. A., & Franco, O. L. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00004 · Cited by 98
Systematically investigating the impact of medication on the gut microbiome
Maier, L., & Typas, A. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.11.001 · Cited by 98
Long term but not short term exposure to obesity related microbiota promotes host insulin resistance
Foley, K. P., Zlitni, S., Denou, E., Duggan, B. M., Chan, R. W., Stearns, J. C., & Schertzer, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-07146-5 · Cited by 86
The alteration of gut microbiota in newly diagnosed type 2 diabetic patients
Chen, P., Chien, Y., & Yang, S. (2018) · Nutrition · doi:10.1016/j.nut.2018.11.019 · Cited by 98
Zhou, W., Xu, H., Zhan, L., Lu, X., & Zhang, L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00232 · Cited by 98
Que, Y., Cao, M., He, J., Zhang, Q., Chen, Q., Yan, C., Lin, A., Yang, L., Wu, Z., Zhu, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722206 · Cited by 98
Zádori, Z., Király, K. P., Al‐Khrasani, M., & Gyires, K. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108327 · Cited by 99
Metformin: New Preparations and Nonglycemic Benefits
Fujita, Y., & Inagaki, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0829-8 · Cited by 99
Exploring the microbiome in health and disease: Implications for toxicology
Scotti, E., Boué, S., Sasso, G. L., Zanetti, F., Belcastro, V., Poussin, C., Sierro, N., Battey, J. N. D., Gimalac, A., Ivanov, N. V., et al. (2017) · Toxicology Research and Application · doi:10.1177/2397847317741884 · Cited by 97
Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice
Sun, C., Chen, L., & Shen, Z. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.011 · Cited by 97
Aspirin in the Prevention of Colorectal Neoplasia
Drew, D. A., & Chan, A. T. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-060319-120913 · Cited by 97
Nguyen, T. T., Kosciolek, T., Daly, R. E., Vázquez-Baeza, Y., Swafford, A., Knight, R., & Jeste, D. V. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.003 · Cited by 83
How Comorbidities Shape Cancer Biology and Survival
Panigrahi, G., & Ambs, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.010 · Cited by 97
Human Gut Microbiota in Health and Alzheimer’s Disease
Szablewski, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170908 · Cited by 91
“Photobiomics”: Can Light, Including Photobiomodulation, Alter the Microbiome?
Liebert, A. D., Bicknell, B. T., Johnstone, D. M., Gordon, L. C., Kiat, H., & Hamblin, M. R. (2019) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2019.4628 · Cited by 96
The emerging role of microbiota-derived short-chain fatty acids in immunometabolism
Jasim, S. A., Opulencia, M. J. C., Ramírez‐Coronel, A. A., Abdelbasset, W. K., Abed, M. H., Markov, A. A., Al‐Awsi, G. R. L., Shamsiev, J. A., Hammid, A. T., Shalaby, M. N., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108983 · Cited by 97
Deep learning methods in metagenomics: a review
Roy, G., Prifti, E., Belda, E., & Zucker, J. (2024) · Microbial Genomics · doi:10.1099/mgen.0.001231 · Cited by 96
Self-citationGut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality?
Morán‐Ramos, S., López-Contreras, B. E., & Canizales‐Quinteros, S. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.11.003 · Cited by 96
Sluggett, J. K., Koponen, M., Bell, J. S., Taipale, H., Tanskanen, A., Tiihonen, J., Uusitupa, M., Tolppanen, A.-M., & Hartikainen, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz234 · Cited by 95
Retracted: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease
Heinzel, S., Aho, V. T. E., Suenkel, U., von Thaler, A., Schulte, C., Deuschle, C., Paulin, L., Hantunen, S., Brockmann, K., Eschweiler, G. W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25788 · Cited by 95
RetractedMikkelsen, K. H., Allin, K. H., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12637 · Cited by 80
van Bommel, E. J. M., Herrema, H., Davids, M., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.11.005 · Cited by 90
Is metformin poised for a second career as an antimicrobial?
Malik, F. R., Mehdi, S. F., Ali, H., Patel, P., Basharat, A., Kumar, A., Ashok, F., Stein, J., Brima, W., Malhotra, P., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2975 · Cited by 96
Gut microbiome differences between metformin‐ and liraglutide‐treated T2 DM subjects
Wang, Z., Saha, S., Van Horn, S., Thomas, E., Traini, C., Sathe, G., Rajpal, D. K., & Brown, J. R. (2018) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.9 · Cited by 82
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 94
Staley, C., Kaiser, T., Vaughn, B. P., Graiziger, C., Hamilton, M. J., Kabage, A. J., Khoruts, A., & Sadowsky, M. J. (2019) · mBio · doi:10.1128/mbio.01586-19 · Cited by 85
The Gut Microbiome in Polycystic Ovary Syndrome and Its Association with Metabolic Traits
Lüll, K., Arffman, R. K., Sola‐Leyva, A., Molina, N. M., Aasmets, O., Herzig, K., Plaza‐Díaz, J., Franks, S., Morin-Papunen, L. C., Tapanainen, J. S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa848 · Cited by 95
The gut microbiome and type 2 diabetes status in the Multiethnic Cohort
Maskarinec, G., Raquinio, P., Kristal, B. S., Setiawan, V. W., Wilkens, L. R., Franke, A. A., Lim, U., Marchand, L. L., Randolph, T. W., Lampe, J. W., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250855 · Cited by 94
Microbiome epidemiology and association studies in human health
VanEvery, H., Franzosa, E. A., Nguyen, L. H., & Huttenhower, C. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00529-x · Cited by 94
Molecular Insight into Gut Microbiota and Rheumatoid Arthritis
Wu, X., He, B., Liu, J., Feng, H., Ma, Y., Li, D., Guo, B., Liang, C., Dang, L., Wang, L., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030431 · Cited by 94
The gut microbiome and hypertension
Pevsner‐Fischer, M., Blacher, E., Tatirovsky, E., Ben‐Dov, I. Z., & Elinav, E. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000293 · Cited by 93
Rosario, D., Benfeitas, R., Bidkhori, G., Zhang, C., Uhlen, M., Shoaie, S., & Mardinoglu, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00775 · Cited by 84
The Mechanism of Action of Biguanides: New Answers to a Complex Question
Magno, L. D., Pastena, F. D., Bordone, R., Coni, S., & Canettieri, G. (2022) · Cancers · doi:10.3390/cancers14133220 · Cited by 92
Genetically engineered bacterium: Principles, practices, and prospects
Liu, Y., Feng, J., Pan, H., Zhang, X., & Zhang, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.997587 · Cited by 92
Chávez-Carbajal, A., Pizano-Zárate, M. L., Hernández-Quiroz, F., Ortíz-Luna, G. F., Morales‐Hernández, R. M., Sales-Millán, A. D., Hernández‐Trejo, M., García-Vite, A., Beltran-Lagunes, L., Hoyo‐Vadillo, C., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8010094 · Cited by 91
Walker, R. L., Vlamakis, H. C., Lee, J. W. J., Besse, L. A., Xanthakis, V., Vasan, R. S., Shaw, S. Y., & Xavier, R. J. (2021) · Genome Medicine · doi:10.1186/s13073-021-01007-5 · Cited by 92
She, J., Tuerhongjiang, G., Guo, M., Liu, J., Hao, X., Guo, L., Liu, N., Xi, W., Zheng, T., Du, B., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.027 · Cited by 91
Yang, Q., Ouyang, J., Sun, F., & Yang, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590685 · Cited by 90
Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases
Hyun, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179139 · Cited by 90
Microbiota and Ocular Diseases
Xue, W., Li, J. J., Zou, Y., Zou, B., & Wei, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759333 · Cited by 90
Self-citationLi, H., Liang, J., Han, M., & Gao, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.004 · Cited by 90
Antibiotic-perturbed microbiota and the role of probiotics
Szajewska, H., Scott, K. P., de Meij, T. G. J., Forslund, S. K., Knight, R. D., Koren, O., Little, P. S., Johnston, B. C., Łukasik, J., Suez, J., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01023-x · Cited by 90
The microbiome and ophthalmic disease
Baim, A. D., Movahedan, A., Farooq, A. V., & Skondra, D. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370218813616 · Cited by 90
The Role of Microbiota in Retinal Disease
Rowan, S., & Taylor, A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-75402-4_53 · Cited by 89
Altered Metabolome of Lipids and Amino Acids Species: A Source of Early Signature Biomarkers of T2DM
Hameed, A., Mojsak, P., Buczyńska, A., Suleria, H. A. R., Kretowski, A. J., & Ciborowski, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072257 · Cited by 89
Tamburini, F. B., Maghini, D., Oduaran, O. H., Brewster, R., Hulley, M. R., Sahibdeen, V., Norris, S. A., Tollman, S., Kahn, K., Wagner, R. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27917-x · Cited by 88
Diabetic cats have decreased gut microbial diversity and a lack of butyrate producing bacteria
Kieler, I. N., Osto, M., Hugentobler, L., Puetz, L., Gilbert, M. T. P., Hansen, T. F., Pedersen, O. B., Reusch, C. E., Zini, E., Lutz, T. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41195-0 · Cited by 88
Self-citationA statistical model for describing and simulating microbial community profiles
Ma, S., Ren, B., Mallick, H., Moon, Y. S., Schwager, E., Maharjan, S., Tickle, T. L., Lu, Y., Carmody, R. N., Franzosa, E. A., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008913 · Cited by 91
Human gut microbiota plays a role in the metabolism of drugs
Jourova, L., Anzenbacher, P., & Anzenbacherova, E. (2016) · Biomedical Papers · doi:10.5507/bp.2016.039 · Cited by 75
Shafi, T., Sirich, T. L., Meyer, T. W., Hostetter, T. H., Plummer, N. S., Hwang, S., Melamed, M. L., Banerjee, T., Coresh, J., & Powe, N. R. (2017) · Kidney International · doi:10.1016/j.kint.2017.05.012 · Cited by 88
Smits, M. M., Fluitman, K. S., Herrema, H., Davids, M., Kramer, M. H. H., Groen, A. K., Belzer, C., de Vos, W. M., Cahen, D. L., Nieuwdorp, M., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101223 · Cited by 75
Sato, K., Yamazaki, K., Kato, T., Nakanishi, Y., Tsuzuno, T., Yokoji, M., Yamada‐Hara, M., Miura, N., Okuda, S., Ohno, H., et al. (2021) · mBio · doi:10.1128/mbio.00771-21 · Cited by 88
Microbiota and neurodegenerative diseases
Marizzoni, M., Provasi, S., Cattaneo, A., & Frisoni, G. B. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000496 · Cited by 76
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Current nutritional and pharmacological anti-aging interventions
Ros, M., & Carrascosa, J. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165612 · Cited by 86
Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma, A., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1437 · Cited by 86
Singh, H., Miyamoto, S., Darshi, M., Torralba, M., Kwon, K., Sharma, K., & Pieper, R. (2020) · Microorganisms · doi:10.3390/microorganisms8091347 · Cited by 86
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 88
Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial
Dagan, S. S., Zelber‐Sagi, S., Zilberman-Schapira, G., Webb, M., Buch, A., Keidar, A., Raziel, A., Sakran, N., Goitein, D., Goldenberg, N. A., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.210 · Cited by 86
Metadata
- Authors
- MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Krogh Pedersen, H., Arumugam, M., Kristiansen, K., Yvonne Voigt, A., Vestergaard, H., Hercog, R., Igor Costea, P., Roat Kultima, J., Li, J., Jørgensen, T., Levenez, F., Dore, J., Bjørn Nielsen, H., Brunak, S., Raes, J., Hansen, T., Wang, J., Dusko Ehrlich, S., Bork, P., & Pedersen, O.
- Affiliations
- Vrije Universiteit Brussel (BE)
- University of Copenhagen (DK)
- Rega Institute for Medical Research (BE)
- European Molecular Biology Laboratory (DE)
- Microbiologie de l’alimentation au service de la santé (FR)
- BGI Group (China) (CN)
- Corresponding author
- Pedersen, Oluf
- ORCID
- Venue
- Nature
- Published
- 2015-12-02
- Volume
- 528
- Issue
- 7581
- Pages
- 262-266
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4681099
- OpenAlex
- W2188930066
- Cited by
- 2,116
- References
- 49
- Citations by year
- 2026: 113 · 2025: 167 · 2024: 212 · 2023: 194 · 2022: 253 · 2021: 270 · 2020: 256 · 2019: 185 · 2018: 197 · 2017: 150 · 2016: 112 · 2015: 3
- FWCI
- 66.83
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-05-04)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Innovationsfonden
- European Molecular Biology Laboratory
- European Commission (600375, 2007–2013, FP7 2007-2013, HORIZON2020, FP7/2007, 305312, 201052, 261376)
- Agence Nationale de la Recherche (ANR-11-DPBS-0001)
- Lundbeckfonden
- Novo Nordisk
- Göteborgs Universitet
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Novo Nordisk Foundation Center for Basic Metabolic Research
- H. Lundbeck A/S
- FP7 Ideas: European Research Council (268985)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- type 2 diabetes, gut microbiota, metformin, antidiabetic drugs, dysbiosis, confounding by treatment, short-chain fatty acids, butyrate, Escherichia, metagenome-wide association study
- MeSH terms
- Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, RNA, Ribosomal, 16S, Biodiversity, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.